Canaccord raised the firm’s price target on Insulet (PODD) to $428 from $399 and keeps a Buy rating on the shares. The firm said Insulet delivered another strong beat-and-raise in Q3, driven by OUS outperformance and record new patient starts in US T1 and US T2.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: